{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:47:12Z","timestamp":1790923632905,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T15:45:16Z","timestamp":1748015116000},"page":"7-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard"],"prefix":"10.1016","volume":"12","author":[{"given":"Guru P.","family":"Sonpavde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.05.008_b0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.05.008_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.24.00340","article-title":"Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0015","first-page":"619","article-title":"Perioperative durvalumab in bladder cancer","volume":"392","author":"Powles","year":"2025","journal-title":"Reply. N Engl J Med"},{"key":"10.1016\/j.euf.2025.05.008_b0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa2401726","article-title":"Adjuvant pembrolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"392","author":"Apolo","year":"2025","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.euf.2025.05.008_b0025","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1200\/JCO.2025.43.5_suppl.659","article-title":"Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA","volume":"43","author":"Galsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0030","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/cncr.24466","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.05.008_b0035","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0040","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0045","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.eururo.2022.07.023","article-title":"Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer","volume":"83","author":"Gil-Jimenez","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.008_b0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.eururo.2023.11.008","article-title":"Spatial relationships in the tumor microenvironment demonstrate association with pathologic response to neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer","volume":"85","author":"Beckabir","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.008_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0060","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.euf.2025.05.008_b0065","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","article-title":"Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma","volume":"85","author":"Powles","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.05.008_b0070","unstructured":"Powles T, Bellmut J, Jensen JB, et al. Clinical outcomes in patients with high-risk post-cystectomy MIBC with persistent circulating tumor DNA-negative status on serial testing: surveillance analysis from the IMvigor011 study. Presented at the 2024 European Association of Urology Conference, Paris, France."},{"issue":"Suppl 2","key":"10.1016\/j.euf.2025.05.008_b0075","doi-asserted-by":"crossref","first-page":"S779","DOI":"10.1016\/j.annonc.2024.08.1270","article-title":"IMpower010: ctDNA status and 5y DFS follow up in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)","volume":"35","author":"Wakelee","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2025.05.008_b0080","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bju.16556","article-title":"Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes","volume":"135","author":"Ben-David","year":"2025","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.05.008_b0085","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2025.05.008_b0090","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/s41467-024-46450-1","article-title":"Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors","volume":"15","author":"Gil-Jimenez","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euf.2025.05.008_b0095","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2025.05.008_b0100","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/bju.15434","article-title":"Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration","volume":"128","author":"Ravi","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.euf.2025.05.008_b0105","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.euf.2025.05.008_b0110","doi-asserted-by":"crossref","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","article-title":"1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial","volume":"35","author":"Bjerggaard Jensen","year":"2024","journal-title":"Ann Oncol"},{"issue":"10 Suppl","key":"10.1016\/j.euf.2025.05.008_b0115","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.014","article-title":"Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816","volume":"19","author":"Forde","year":"2024","journal-title":"J Thorac Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240545692500121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:58:05Z","timestamp":1770145085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240545692500121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S240545692500121X"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.008","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Adjuvant Therapy in Current Perioperative Immunotherapy-based Trials in Bladder Cancer: A Justified Standard","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}